155 related articles for article (PubMed ID: 17704517)
1. Determination of disc breakpoints and evaluation of Etests for tigecycline susceptibility testing by the BSAC method.
Hope R; Parsons T; Mushtaq S; James D; Livermore DM
J Antimicrob Chemother; 2007 Oct; 60(4):770-4. PubMed ID: 17704517
[TBL] [Abstract][Full Text] [Related]
2. Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-non-susceptible Acinetobacter spp.
Casal M; Rodríguez F; Johnson B; Garduno E; Tubau F; de Lejarazu RO; Tenorio A; Giménez MJ; Bartolomé R; Garcia-Rey C; Aguilar L; García-Escribano N
J Antimicrob Chemother; 2009 Jul; 64(1):69-72. PubMed ID: 19451133
[TBL] [Abstract][Full Text] [Related]
3. Tigecycline activity: low resistance rates but problematic disc breakpoints revealed by a multicentre sentinel survey in the UK.
Hope R; Mushtaq S; James D; Pllana T; Warner M; Livermore DM;
J Antimicrob Chemother; 2010 Dec; 65(12):2602-9. PubMed ID: 20930043
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility to tigecycline of isolates from samples collected in hospitalized patients with secondary peritonitis undergoing surgery.
Tubau F; Liñares J; Rodríguez MD; Cercenado E; Aldea MJ; González-Romo F; Torroba L; Berdonces P; Plazas J; Aguilar L; Delgado A; García-Escribano N;
Diagn Microbiol Infect Dis; 2010 Mar; 66(3):308-13. PubMed ID: 20022193
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of tigecycline against 2423 clinical isolates and comparison of the available interpretation breakpoints.
Papaparaskevas J; Tzouvelekis LS; Tsakris A; Pittaras TE; Legakis NJ;
Diagn Microbiol Infect Dis; 2010 Feb; 66(2):187-94. PubMed ID: 19836184
[TBL] [Abstract][Full Text] [Related]
6. Validation and reproducibility assessment of tigecycline MIC determinations by Etest.
Bolmström A; Karlsson A; Engelhardt A; Ho P; Petersen PJ; Bradford PA; Jones CH
J Clin Microbiol; 2007 Aug; 45(8):2474-9. PubMed ID: 17522277
[TBL] [Abstract][Full Text] [Related]
7. Comparative activity of tigecycline and tetracycline on Gram-negative and Gram-positive bacteria revealed by a multicentre study in four North European countries.
Nilsson LE; Frimodt-Møller N; Vaara M; Simonsen GS;
Scand J Infect Dis; 2011 Sep; 43(9):707-13. PubMed ID: 21619494
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
[TBL] [Abstract][Full Text] [Related]
9. A longitudinal analysis of antimicrobial susceptibility in clinical institutions in Germany as part of the Tigecycline Evaluation and Surveillance Trial (2004-2007).
Seifert H; Dowzicky MJ
Chemotherapy; 2009; 55(4):241-52. PubMed ID: 19468222
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second multicenter study.
Betriu C; Rodríguez-Avial I; Gómez M; Culebras E; López F; Alvarez J; Picazo JJ;
Diagn Microbiol Infect Dis; 2006 Dec; 56(4):437-44. PubMed ID: 16949245
[TBL] [Abstract][Full Text] [Related]
11. BSAC standardized disc susceptibility testing method (version 7).
Andrews JM;
J Antimicrob Chemother; 2008 Aug; 62(2):256-78. PubMed ID: 18474513
[TBL] [Abstract][Full Text] [Related]
12. Epidemiological MIC cut-off values for tigecycline calculated from Etest MIC values using normalized resistance interpretation.
Kronvall G; Karlsson I; Walder M; Sörberg M; Nilsson LE
J Antimicrob Chemother; 2006 Mar; 57(3):498-505. PubMed ID: 16410264
[TBL] [Abstract][Full Text] [Related]
13. Multicenter study to assess the in vitro activity of tigecycline by disk diffusion test against clinical isolates from Argentina.
Fernández Canigia L; Kaufman S; Lanata L; Vay C; Giovanakis M; Bantar C;
Chemotherapy; 2009; 55(1):20-7. PubMed ID: 18974645
[TBL] [Abstract][Full Text] [Related]
14. Effect of medium type, age and aeration on the MICs of tigecycline and classical tetracyclines.
Hope R; Warner M; Mushtaq S; Ward ME; Parsons T; Livermore DM
J Antimicrob Chemother; 2005 Dec; 56(6):1042-6. PubMed ID: 16286361
[TBL] [Abstract][Full Text] [Related]
15. In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan determined by the broth microdilution and disk diffusion methods.
Liao CH; Kung HC; Hsu GJ; Lu PL; Liu YC; Chen CM; Lee CM; Sun W; Jang TN; Chiang PC; Cheng YJ; Lin HC; Shi ZY; Wang LS; Chuang YC; Tsao SM; Lu CT; Liu JW; Huang CH; Hsueh PR
Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S192-6. PubMed ID: 19013354
[TBL] [Abstract][Full Text] [Related]
16. Tigecycline in vitro activity against gram-negative and gram-positive pathogens collected in Italy.
Roveta S; Marchese A; Debbia EA
Chemotherapy; 2008; 54(1):43-9. PubMed ID: 18073470
[TBL] [Abstract][Full Text] [Related]
17. Tigecycline activity tested against 11808 bacterial pathogens recently collected from US medical centers.
Gales AC; Sader HS; Fritsche TR
Diagn Microbiol Infect Dis; 2008 Apr; 60(4):421-7. PubMed ID: 18068934
[TBL] [Abstract][Full Text] [Related]
18. In vitro activities of tigecycline combined with other antimicrobials against multiresistant gram-positive and gram-negative pathogens.
Vouillamoz J; Moreillon P; Giddey M; Entenza JM
J Antimicrob Chemother; 2008 Feb; 61(2):371-4. PubMed ID: 18033780
[TBL] [Abstract][Full Text] [Related]
19. Comparison of three standardized disc susceptibility testing methods for colistin.
Tan TY; Ng LS
J Antimicrob Chemother; 2006 Oct; 58(4):864-7. PubMed ID: 16905528
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST).
Bouchillon SK; Iredell JR; Barkham T; Lee K; Dowzicky MJ
Int J Antimicrob Agents; 2009 Feb; 33(2):130-6. PubMed ID: 18995992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
